Travere Therapeutics, Inc. Share Price & Technical Analysis
TVTX · $44.43 (-0.69%)
Healthcare / Biotechnology
$44.43
-0.69%
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola an…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
4% return in May, -3% avg return in past 3 year May month.
22% return in 2026, 50% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -20% | -4% | 1% | 40% | 4% | – | – | – | – | – | – | – | 22% |
| 25 | 16% | 8% | -16% | 14% | -28% | -3% | 5% | 15% | 38% | 52% | 2% | 9% | 115% |
| 24 | 1% | -15% | 0% | -29% | 35% | 11% | 16% | -1% | 47% | 28% | 4% | -8% | 90% |
| 23 | 5% | 0% | 3% | -5% | -17% | -14% | 12% | -16% | -38% | -26% | -3% | 45% | -54% |
| 22 | -12% | 0% | -6% | -3% | -6% | 4% | -2% | 15% | -8% | -14% | -8% | 4% | -35% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Strong
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.93B
P/E ratio
—
52W high
$48.61
52W low
$13.88
Volume
8,03,425
Beta
1.14
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Travere Therapeutics, Inc. share price today?
- Travere Therapeutics, Inc. (TVTX) last traded around $44.43 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TVTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TVTX. Download the app for real-time alerts.
- How can I analyze Travere Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.